In this study, we revealed that AURKA inhibitor MLN8237 upregulated the expression of PD-L1 in breast cancer by increasing the level of p-STAT3 and impeding the infiltration of CD3+ T and CD8+ T cells in tumor tissues, thus impaired antitumor immune response. Here, CD8A is linked to breast carcinoma.